Skip to main content
SpringerLink
Log in

The role of iron supplementation during epoietin treatment for cancer-related anemia

  • REVIEW
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Cancer-related anemia is common and multifactorial in origin. Functional iron deficiency (FID) is now recognized as a cause of iron-restricted erythropoiesis and may be one of the major reasons for lack of response to treatment with Erythropoietic Stimulating Agents (ESAs). Numerous studies have shown that intravenous (IV), but not oral, iron therapy effectively provides sufficient iron for optimal erythropoiesis in anemic patients with chronic renal disease receiving ESA therapy. The use of IV iron has also been suggested in the cancer setting. Six recent studies have tested this assumption and are summarized in this review. Four formulations of IV iron are available in Europe, with different pharmacokinetics, iron bioavailability, and risk of acute adverse drug reactions. Conclusion: Limited iron stores and FID are common causes of response failure during ESA treatment in cancer patients and should be diagnosed. There is now substantial scientific support for the use of IV iron supplementation to improve response and this has been acknowledged in international and national guidelines. Prospective long-term data on the safety of IV iron in this setting are still awaited. Recommendations concerning the optimal formulation, doses, and schedule of iron supplementation to ESA treatment in cancer-related anemia are provisional awaiting data from prospective, randomized trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ludwig H, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293–306.

    Article  PubMed  Google Scholar 

  2. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001;91:2214–21.

    Article  PubMed  CAS  Google Scholar 

  3. Del Mastro L, et al. Randomized phase III trail evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol. 1997;15:2715–21.

    PubMed  Google Scholar 

  4. Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol. 2001;28:1–6.

    Article  PubMed  CAS  Google Scholar 

  5. Nowrousian MR. Pathophysiology of cancer-related anemia. In: Nowrousian MR, editor. Recombinant human erythropoietin (rhEPO) in clinical oncology – scientific and clinical aspects of anemia in cancer. Springer: Wien; 2002. p. 39–62.

    Google Scholar 

  6. Konijn AM, Hershko C. Ferritin synthesis in inflammation. I. Pathogenesis of impaired iron release. Br J Haematol. 1977;37:7–16.

    PubMed  CAS  Google Scholar 

  7. Viatte L, et al. Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice. Blood. 2006;107:2952–8.

    Article  PubMed  CAS  Google Scholar 

  8. Rivera S, et al. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood. 2005;105:1797–802.

    Article  PubMed  CAS  Google Scholar 

  9. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–23.

    Article  PubMed  CAS  Google Scholar 

  10. Roy CN, Andrews NC. Anaemia of inflammation: the hepcidin link. Curr Opin Haematol. 2005;12:107–11.

    Article  CAS  Google Scholar 

  11. Locatelli F, et al. Anemia management for hemodialysis patients: kidney disease outcomes quality initiative (K/DOQI) guidelines and dialysis outcomes and practice patterns study (DOPPS) findings. Am J Kidney Dis. 2004;44 (Suppl 2):S27–33.

    Article  Google Scholar 

  12. Punnonen K, Irjala K, Rajamäki A. Serum transferrin receptor and its ration to s-ferritin in the diagnosis of iron deficiency. Blood. 1997;89:1052–7.

    PubMed  CAS  Google Scholar 

  13. Fishbane S, Galgano S, Langley RC Jr, Canfield W, Maesaka JK. Reticulocyte hemoglobin content in the evaluation or iron status of hemodialysis patients. Kidney Int. 1997;52:217–22.

    Article  PubMed  CAS  Google Scholar 

  14. Macdougall IC. What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patients on rhEPO therapy? Merits of percentage of hypochromic red cells as a marker of functional iron deficiency. Nephrol Dial Transplant. 1998;13:847–9.

    Article  PubMed  CAS  Google Scholar 

  15. Mast AE, Blinder MA, Lu Q, Flax S, Dietzen DJ. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood. 2002;99:1489–91.

    Article  PubMed  CAS  Google Scholar 

  16. Brugnara C, Schiller B, Moran J. Reticulocyte haemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol. 2006;28:303–8.

    Article  PubMed  CAS  Google Scholar 

  17. Thomas C, Kirschbaum A, Boehm D, Thomas L. The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy. Med Oncol. 2006;23:23–36.

    Article  PubMed  CAS  Google Scholar 

  18. Katodritou E, et al. Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. Lab Hematol. 2006;12:47–54.

    Article  PubMed  Google Scholar 

  19. Katodritou E, et al. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Ann Hematol. 2007;86:369–76.

    Article  PubMed  CAS  Google Scholar 

  20. Franck S, Linssen J, Messinger M, Thomas L. Potential utility of Ret-Y in the diagnosis of iron restricted erythropoiesis. Clin Chem. 2004;50:1240–2.

    Article  PubMed  CAS  Google Scholar 

  21. Henry DH. Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist. 1998;3:275–8.

    PubMed  CAS  Google Scholar 

  22. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol. 1998;25 (3 Suppl 7):43–6.

    PubMed  CAS  Google Scholar 

  23. Crawford J, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95:888–95.

    Article  PubMed  CAS  Google Scholar 

  24. Rizzo JD, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 ASH/ASCO clinical practice guideline update. Blood. 2008;111:25–41.

    Article  PubMed  CAS  Google Scholar 

  25. Bokemeyer C, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007;43:258–70.

    Article  PubMed  CAS  Google Scholar 

  26. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Cancer- and treatment-related anemia. V.1.2008. http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf.

  27. Mikhael J, Melosky B, Cripps C, Rayson D, Kouroukis CT. Canadian supportive care recommendations for the management of anemia in patients with cancer. Curr Oncol. 2007;14:209–17.

    Article  PubMed  CAS  Google Scholar 

  28. Henry DH. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies. Drugs. 2007;67:175–94.

    Article  PubMed  CAS  Google Scholar 

  29. Bennett CL, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia:. JAMA. 2008;299:914–24.

    Article  PubMed  CAS  Google Scholar 

  30. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin – an updated overview. Nat Clin Pract Oncol. 2006;3:152–64.

    Article  PubMed  CAS  Google Scholar 

  31. Henke M, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255–60.

    Article  PubMed  CAS  Google Scholar 

  32. Leyland-Jones B, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23:5960–72.

    Article  PubMed  CAS  Google Scholar 

  33. Overgaard J, et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): the Danish Head and Neck Cancer Group DAHANCA 10 rand (abstract). Eur J Cancer. 2007;5(Suppl):7.

    Google Scholar 

  34. Wright JR, et al. Randomized, double blind, placebo-controlled trial of erythropoietin in non-small-cell lungacancer with disease-related anemia. J Clin Oncol. 2007;25:1027–32.

    Article  PubMed  CAS  Google Scholar 

  35. Smith RE Jr, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase lll, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008;26:1040–50.

    Article  PubMed  CAS  Google Scholar 

  36. Mano M, et al. Current role of erythropoietin in the management of patients with haematological and solid malignancies. Cancer Ther. 2005;3A:41–56.

    Google Scholar 

  37. Glaspy J, Cavill I. Role of iron in optimizing responses of anemic cancer patients to erythropoetin. Oncology. 1999;13:461–73.

    PubMed  CAS  Google Scholar 

  38. Cavill I. Iron and erythropoietin in renal disease. Nephrol Dial Transplant. 2002;17 (Suppl 5):19–23.

    Article  PubMed  CAS  Google Scholar 

  39. Cavill I, et al. Iron and the anaemia of chronic disease: a review and strategic recommendations. Curr Med Res Opin. 2006;22:731–7.

    Article  PubMed  CAS  Google Scholar 

  40. Vreugdendhil G, et al. Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis. Ann Hematol. 1992;65:265–8.

    Article  Google Scholar 

  41. Goch J, Birgegård G, Danielson BG, Wikström B. Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test. Nephron. 1996;73:403–6.

    Article  PubMed  CAS  Google Scholar 

  42. Savonije JH, et al. Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia. Cancer Invest. 2006;24:562–6.

    Article  PubMed  CAS  Google Scholar 

  43. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin dose by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26:41–6.

    Article  PubMed  CAS  Google Scholar 

  44. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int. 1999;69(Suppl):S61–6.

    Article  CAS  Google Scholar 

  45. Besarab A, Frinak S, Yee J. An indistinct balance: the safety and efficacy of parenteral iron therapy. J Am Soc Nephrol. 1999;10:2029–43.

    PubMed  CAS  Google Scholar 

  46. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004;53:1190–7.

    Article  PubMed  CAS  Google Scholar 

  47. Schröder O, et al. Intravenous iron sucrose versus oral iron supplementation for treatment of iron deficiency anemia in patients with inflammatory bowel disease – a randomized, controlled, open-label, muticenter study. Am J Gastroenterol. 2005;100:2503–9.

    Article  PubMed  CAS  Google Scholar 

  48. Lindgren S, Befrits R, Wikman O, Hjortswang H. Intravenous iron sucrose compared to oral iron in anaemia management in IBD patients – a randomized, controlled, open label multicenter study. 14th UEGW Berlin 2006. Gut. 2006;55 Suppl Nov. (Abs).

  49. Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. BJOG. 2006;113:1248–52.

    Article  PubMed  CAS  Google Scholar 

  50. KDOQI Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(Suppl 3).

  51. Gasche C, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545–53.

    Article  PubMed  Google Scholar 

  52. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol. 2004;15:S93–8.

    PubMed  Google Scholar 

  53. Danielson BG, Salmonson T, Derendorf H, Geisser P. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Drug Res. 1996;46:615–21.

    CAS  Google Scholar 

  54. Beshara S, et al. Pharmacokinetics and red cell utilization of iron(lll) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. Br J Haematol. 1999;104:296–302.

    Article  PubMed  CAS  Google Scholar 

  55. Beshara S, et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anemic patients using positrob emission tomography. Br J Haematol. 2003;103:853–9.

    Article  Google Scholar 

  56. Wood JK, Milner PFA, Pathak UN. The metabolism of iron-dextran given as a total-dose infusion to iron deficient Jamaican subjects. Br J Haematol. 1968;14:119–29.

    Article  PubMed  CAS  Google Scholar 

  57. Beguin Y. Intravenous iron and recombinant human erythropoietin in cancer patients. J Clin Oncol. 2005;23:651–2.

    Article  PubMed  Google Scholar 

  58. Auerbach M, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004;22:1301–7.

    Article  PubMed  CAS  Google Scholar 

  59. Beguin Y. Intravenous iron and recombinant human erythropoietin in cancer patients. J Clin Oncol. 2005;23:651–3.

    Article  PubMed  Google Scholar 

  60. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12:231–42.

    Article  PubMed  CAS  Google Scholar 

  61. Hedenus M, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007;21:627–32.

    PubMed  CAS  Google Scholar 

  62. Birgegård G, Wide L, Simonsson B. Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation. Br J Haematol. 1989;72:462–6.

    Article  PubMed  Google Scholar 

  63. Nemeth E, et al. Il-6 mediates hypoferremia in inflammation by inducing the synthesis of the iron regulatory hormone, hepcidin. J Clin Invest. 2004;113:1271–6.

    PubMed  CAS  Google Scholar 

  64. Bastit L, et al. Intravenous iron supplementation in patiens with chemotherapy-induced anemia receiving darbepoetin alfa every three weeks: iron parameters in a randomized controlled trial. J Clin Oncol. 2008;26:1611–8.

    Article  PubMed  CAS  Google Scholar 

  65. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008;26:1619–25.

    Article  PubMed  CAS  Google Scholar 

  66. Bellet RE, et al. A phase 3 randomized controlled study comparing iron sucrose intravenously to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent therapy. Proc Am Soc Clin Oncol. 2007;25:9109.

    Google Scholar 

  67. Hedenus M, Näsman Per, Liwing J. Economic evalutation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. J Clin Pharmacy Therapeutics 2008 (in press).

  68. Auerbach M, Pappadakis J, Doherty E. Therapeutic and financial optimization of anemia management in cancer patients with chemotherapy-related anemia through low molecular weight (LMW) iron dextran administration. Am Coll Clin Pharmacy Annual Meeting, Denver, Colorado. 2007;abs 188.

  69. Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral formulations: a quantitative and comparative study. Nephrol Dial Transplant. 2004;19:561–5.

    Article  PubMed  CAS  Google Scholar 

  70. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002;40:90–103.

    Article  PubMed  CAS  Google Scholar 

  71. Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant. 2005;20:1443–9.

    Article  PubMed  CAS  Google Scholar 

  72. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21:378–82.

    Article  PubMed  CAS  Google Scholar 

  73. Critchley J, Dundar Y. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review. Transfus Altern Transfus Med. 2007;9:8–36.

    Article  Google Scholar 

  74. Hörl WH. Should we still use iron dextran in hemodialysis patients? Am J Kidney Dis. 2001;37:859–61.

    Article  PubMed  Google Scholar 

  75. Grasso P. Sarcoma after intramuscular iron injection. Br Med J. 1973;2:667.

    PubMed  CAS  Google Scholar 

  76. Deicher R, Ziai F, Cohen G, Müllner M, Hörl WH. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int. 2003;64:728–36.

    Article  PubMed  CAS  Google Scholar 

  77. Aronoff GR, et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int. 2004;66:1193–8.

    Article  PubMed  CAS  Google Scholar 

  78. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol. 1998;9:869–76.

    PubMed  CAS  Google Scholar 

  79. Erichsen K, et al. Oral versus intravenous iron therapy in patients with inflammatory bowel disease. Scand J Gastroenterol. 2005;40:1–8.

    Article  CAS  Google Scholar 

  80. Scheiber-Mojdehkar B, Lutzky B, Schaufler R, Sturm B, Goldenberg H. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation. J Am Soc Nephrol. 2004;15:1648–55.

    Article  PubMed  CAS  Google Scholar 

  81. Feldman HI, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004;15:1623–32.

    Article  PubMed  CAS  Google Scholar 

  82. Weiss G, Gordeuk VR. Benefits and risks of iron therapy for chronic anaemias. Eur J Clin Invest. 2005;35 (Suppl 3):36–45.

    Article  PubMed  CAS  Google Scholar 

  83. Weinberg ED. The role of iron in cancer. Eur J Cancer Prev. 1996;5:19–36.

    PubMed  CAS  Google Scholar 

  84. Kew MD. Pathogenesis of hepatocellular carcinoma in hereditary hemochromatosis: occurrence in noncirrhotic patients. Hepatology. 1990;11:1086–7.

    Article  PubMed  CAS  Google Scholar 

  85. Ali M, et al. Hemosiderosis in hemodialysis patients. An autopsy study of 50 cases. JAMA. 1980;244:343–5.

    Article  PubMed  CAS  Google Scholar 

  86. Le N, Richardsson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta. 2002;1603:31–46.

    PubMed  CAS  Google Scholar 

  87. Merk K, et al. The incidence of cancer among blood donors. Int J Epidemiol. 1990;19:505–9.

    Article  PubMed  CAS  Google Scholar 

  88. Zacharski LR, et al. Reducing iron stores lowers cancer risk in patients with peripheral arterial disease. Blood (ASH Annual Meeting Abstracts). 2007;110:2665.

  89. Kalantar-Zadeh K, Regidor DL, McAllister CI, Michael B, Warmock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;3:772–89.

    Google Scholar 

Download references

Acknowledgement

Disclosures of interest

Both authors have received honoraria from Amgen, Roche, Janssen-Cilag and Renapharma Sweden for lectures and attending advisory boards.

Author information

Authors and Affiliations

  1. Department of Medicine, Sundsvall Hospital, 851 86, Sundsvall, Sweden

    M. Hedenus

  2. Department of Hematology, University Hospital, Uppsala, Sweden

    G. Birgegård

Authors
  1. M. Hedenus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Birgegård
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Hedenus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hedenus, M., Birgegård, G. The role of iron supplementation during epoietin treatment for cancer-related anemia. Med Oncol 26, 105–115 (2009). https://doi.org/10.1007/s12032-008-9072-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-008-9072-0

Keywords

Search

Navigation